Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results
Date:2/28/2012

result, our ability to respond to the comments raised by the FDA regarding our manufacturing process may exceed the timeframe we currently anticipate and we cannot assure that we will be capable of generating the data requested by the FDA in the timeframe we anticipate. In addition, the FDA may request additional data, require additional conformance batches, delay any decision past the time frames anticipated by us, or deny the approval of the industrial scale manufacturing process. If the manufacturing capacity expansion projects at Sanquin are delayed, or do not result in the capacity we anticipate, if Sanquin cannot obtain necessary regulatory approvals for the contemplated facility expansions in the time frames we anticipate or if we are not able to manufacture the anticipated volume of product at the existing scale, we may not be able to satisfy patient demand. Our inability to obtain adequate product supplies to satisfy our patient demand may create opportunities for our competitors and we will suffer a loss of potential future revenues. These factors, and other factors, including, but not limited to those described in ViroPharma's annual report on Form 10-K for the year ended December 31, 2011, could cause future results to differ materially from the expectations expressed in this press release. The forward-looking statements contained in this press release may become outdated over time. ViroPharma does not assume any responsibility for updating any forward-looking statements. VIROPHARMA INCORPORATEDSelected Financial InformationConsolidated Statements of Operations:Three months endedTwelve months ended(in thousands, except per share data)

December 31,December 31,2011201020112010(unaudited)Revenue:Net product sales

$ 145,575$ 121,623$ 544,374$ 439,012Costs and Expenses:Cost of sales (excluding amortization of product rights)

19,68317,93479,97661,288Research and development

12,70710,46066,47739,613Selling, general and administrativ
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three September Healthcare Conferences
2. ViroPharma to Present at Three October Healthcare Conferences
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
5. ViroPharma to Present at Three November Healthcare Conferences
6. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
7. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
8. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
9. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
10. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
11. ViroPharma to Present at Two June Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Geneva, Switzerland (PRWEB) July 30, 2014 ... proven technologies for biologic drug discovery and mammalian cell ... SURE CHO-Mplus Libraries ™ will be presented at ... conference being held, September 8 – 10, 2014 ... Berkeley, California. , The following abstract will be ...
(Date:7/30/2014)... , July 30, 2014   Wyle ... the Fully Integrated Lifecycle Mission Support Services (FILMSS) ... Administration (NASA). Under the terms of the contract, ... Center at Moffett Field, Calif. In particular, Wyle ... bioscience flight development projects on the International Space ...
(Date:7/30/2014)... July 30, 2014 July 30, 2014. ... a biotechnology firm that provides DNA-based authentication and security ... Ph.D. Vice President of Life Sciences, a newly created ... , Dr. Hogan will lead APDN’s drive to build ... with biotech and healthcare customers, provide guidance to APDN’s ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Vycom announces ... of products, designed to meet Factory Mutual (FM) 4910 ... materials such as wet benches, process tools, fume hoods, ... safety and damage to semiconductor wafers used in electronic ... a flame-retardant PVC solution with excellent workability and superior ...
Breaking Biology Technology:Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 2Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 3Wyle Wins NASA's Fully Integrated Lifecycle Mission Support Services Contract 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 3Vycom Announces Flametec® Thermax PVC (FM4910 Listed) For a Variety of Clean Room Applications with Excellent Workability and Aesthetics 2
... NORTH BILLERICA, Mass., Sept. 9 Seahorse Bioscience, Inc., the ... cellular bioenergetics, today announced it will present data with the ... Flux Analyzer in revealing the effects of KSR1 and nutrients ... The data will appear in two posters at the AACR ...
... , NEW YORK, Sept. 9 ... Vice President and General Manager of Informatics at Thermo Fisher ... HUNT Research Center and Biobank, about data integration: the benefits ... life sciences companies. , , ...
... , WATERTOWN, Mass., Sept. 9 EnVivo Pharmaceuticals ... vice president and chief financial officer. DiPalma is responsible ... and operations. , , "EnVivo has grown ... to help better manage our broad pipeline and increasing business ...
Cached Biology Technology:Seahorse Bioscience to Present Novel Cellular Bioenergetics Data in Collaboration with University of Nebraska at AACR Metabolism and Cancer Conference 2Don't Wait to Innovate: Future Pharmaceuticals Magazine Releases Its Issue on Innovation in IT, Cell-Based Therapy and Supply Chains 2EnVivo Pharmaceuticals Names Stephen DiPalma Chief Financial Officer 2
(Date:7/30/2014)... A deep-sea octopus protected and tended her eggs until ... published July 30, 2014 in the open-access journal ... Aquarium Research Institute and colleagues. , Octopuses typically have ... females protect and take care of their fertilized eggs ... eggs for 1 to 3 months, but little is ...
(Date:7/30/2014)... the University of Helsinki and the Universitat Autnoma de ... morphological changes which have taken millions of years to ... development of mice teeth, induced in the laboratory, scientists ... those observed in the fossil registry of rodent species ... , To modify the development of their teeth, the ...
(Date:7/30/2014)... associate professor Andrew S. Mount, performed cutting-edge research on ... novel anti-fouling paint for ships and boats and also ... team,s findings, published in Nature Communications ... attaches to a wide variety of surfaces using highly ... underwater heavy-duty adhesive. , "In previous research, we were ...
Breaking Biology News(10 mins):Deep-sea octopus has longest-known egg-brooding period 2Scientists reproduce evolutionary changes by manipulating embryonic development of mice 2Study: Marine pest provides advances in maritime anti-fouling and biomedicine 2
... professors are leading research teams that will work ... and the Caribbean to increase food production, improve ... change. The projects are part of the Sustainable ... Program (SANREM CRSP), a $15 million, five-year program ...
... study from Children,s Hospital Boston and the Boston-based Autism Consortium ... known as chromosomal microarray analysis, has about three times the ... (ASDs) than standard tests. Publishing in the April issue of ... that CMA become part of the first-line genetic work-up for ...
... WINSTON-SALEM, N.C. Vitamin D is quickly becoming the "go-to" ... to atherosclerosis. However, new evidence from a Wake Forest University ... those with low levels may have different effects based on ... do harm. The study is the first to ...
Cached Biology News:Researchers introducing sustainable agriculture practices to improve food security 2Researchers introducing sustainable agriculture practices to improve food security 3A better genetic test for autism 2A better genetic test for autism 3Vitamin D levels have different effects on atherosclerosis in blacks and whites 2Vitamin D levels have different effects on atherosclerosis in blacks and whites 3
... is most widely used in combination ... differentially stain nucleic acids following polyacrylamide ... solution, Pyronin Y stains RNA red, ... Chem comp: Dye content ...
... The loxP-cm-loxP cassette is ... prokaryotic cells. The prokaryotic promoter ... resistance is a slightly modified version ... higher transcription efficiency than the generally ...
... Agencourt AMPure is a ... that requires no sample transfer, ... efficiently purifies small and large ... or 384-well microplates. Agencourt AMPure ...
... is a magnetic bead-based PCR ... sample transfer, centrifugation or filtration ... and large PCR extension products ... Agencourt AMPure can easily be ...
Biology Products: